GO:0005148 prolactin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005148 (prolactin receptor binding) is a molecular function defined as binding to a prolactin receptor, with the primary ligand being the hormone prolactin (PRL).
• Prolactin receptor binding initiates a sequential, ordered interaction in which prolactin first engages site 1 of the receptor dimer, followed by site 2, a mechanism critical for receptor activation.
• The prolactin receptor (PRLR) is a cytokine receptor superfamily member that signals through JAK2/STAT5 and is implicated in breast cancer, prostate cancer, and endocrine disorders.
• Mutational analyses have mapped key ligand-binding determinants in both prolactin and its receptor, enabling the design of antagonists with therapeutic potential.
• Quantitative binding assays remain essential for measuring prolactin-receptor affinity and for screening antagonists.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are powerful tools to dissect the causal roles of PRL and PRLR in physiology and disease.
Description
Prolactin receptor binding (GO:0005148) is a molecular function that describes the binding of a ligand to a prolactin receptor (PRLR). The principal physiological ligand is the pituitary hormone prolactin (PRL), although other lactogenic hormones can also engage the receptor. This binding event is the first step in a signaling cascade that controls mammary gland development, lactation, reproduction, and immune regulation. Dysregulated prolactin receptor binding and signaling have been linked to breast cancer, prostate cancer, and endocrine disorders, making it a target of intense research. Understanding the structural and mechanistic details of this interaction is therefore essential for both basic biology and therapeutic development.
prolactin receptor binding At A Glance
| GO ID | GO:0005148 |
|---|---|
| GO term | prolactin receptor binding |
| Ontology | molecular_function |
| Synonym | prolactin, prolactin receptor ligand |
| Major function | Binding to a prolactin receptor, initiating receptor activation and signaling. |
| Primary ligand | Prolactin (PRL). |
| Receptor | Prolactin receptor (PRLR), a cytokine receptor superfamily member. |
| Downstream signaling | JAK2/STAT5, MAPK, PI3K pathways. |
| Disease relevance | Breast cancer, prostate cancer, hyperprolactinemia. |
What Is GO:0005148?
According to the Gene Ontology, GO:0005148 (prolactin receptor binding) is defined as binding to a prolactin receptor. In other words, it is the molecular function of a ligand (typically the hormone prolactin) physically interacting with the prolactin receptor protein. This binding event is highly specific and is the initial trigger for receptor dimerization and downstream signal transduction.
Why Is prolactin receptor binding Important in Cell Biology?
Prolactin receptor binding is the gateway to a wide array of physiological processes, including lactation, reproduction, and immune modulation. Its dysregulation is implicated in cancer progression, particularly in breast and prostate cancers, where autocrine/paracrine prolactin loops drive proliferation. Moreover, the ordered binding mechanism offers a paradigm for understanding cytokine receptor activation. Consequently, studying this interaction provides insights into fundamental cell signaling and identifies targets for therapeutic intervention, such as prolactin receptor antagonists.
• Initiates prolactin signaling, essential for mammary gland development and lactation.
• Regulates reproductive functions, including ovulation and corpus luteum maintenance.
• Modulates immune responses through prolactin receptor expression on immune cells.
• Drives oncogenic signaling in breast and prostate cancers.
• Serves as a target for antagonist development to treat hyperprolactinemia and cancer.
• Provides a model for understanding sequential receptor binding in cytokine receptors.
• Enables quantitative binding assays for drug screening.
• Involves mutational hotspots that can be explored with CRISPR editing.
What Happens During prolactin receptor binding?
Ligand recognition and initial contact
In simple terms: Prolactin first grabs onto one side of the receptor.
Prolactin binds to the prolactin receptor via a two-site mechanism. The first contact occurs at site 1 of the receptor, which involves high-affinity interactions with the receptor's extracellular domain. This step is critical for subsequent receptor dimerization and activation.
Ordered binding and receptor dimerization
In simple terms: After the first grab, prolactin pulls two receptor molecules together.
Following site 1 engagement, prolactin binds to a second receptor molecule at site 2, leading to receptor dimerization. This ordered binding is essential for bringing the intracellular domains into proximity, allowing JAK2 transphosphorylation and downstream signaling.
Conformational changes and signal initiation
In simple terms: The receptor changes shape and sends a signal inside the cell.
Ligand-induced dimerization triggers conformational changes in the receptor's intracellular domain, facilitating JAK2 activation and phosphorylation of STAT5. This initiates transcription of prolactin-responsive genes.
Negative feedback and receptor turnover
In simple terms: The cell has ways to shut down the signal.
Prolactin receptor signaling is attenuated by internalization, degradation, and negative regulators such as SOCS proteins. This feedback prevents prolonged activation and is often disrupted in cancer.
Key Genes Involved in GO:0005148 prolactin receptor binding
The following genes and proteins are central to prolactin receptor binding and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PRL | Encodes prolactin, the primary ligand for prolactin receptor binding. | Knockout models show lactation failure; overexpression linked to cancer. |
| PRLR | Encodes the prolactin receptor, the binding target. | Mutations affect binding affinity; knockout blocks signaling. |
| JAK2 | Tyrosine kinase that associates with PRLR and initiates signaling. | Inhibitors and mutations used to dissect pathway. |
| STAT5A | Transcription factor activated by PRLR signaling. | Knockout impairs mammary development. |
| STAT5B | Transcription factor activated by PRLR signaling. | Mediates metabolic and immune effects. |
| SOCS1 | Negative regulator of PRLR signaling. | Overexpression reduces prolactin responses. |
| SOCS3 | Negative regulator of PRLR signaling. | Modulates feedback in cancer models. |
| CISH | Cytokine-inducible SH2-containing protein, inhibits STAT5. | Regulates prolactin sensitivity. |
| PTPN11 | Phosphatase that modulates JAK2/STAT5. | Mutations affect signaling output. |
| GHR | Growth hormone receptor, related to PRLR. | Cross-reactivity studies. |
| CSH1 | Placental lactogen, alternative ligand. | Binds PRLR with lower affinity. |
| CSH2 | Placental lactogen variant. | Ligand specificity studies. |
| PRLHR | Prolactin-releasing hormone receptor, upstream regulator. | Controls prolactin secretion. |
| ESR1 | Estrogen receptor alpha, regulates PRL expression. | Crosstalk in breast cancer. |
| FOXA1 | Transcription factor regulating PRLR expression. | Lineage-specific effects. |
| GATA3 | Transcription factor regulating PRLR expression. | Breast cancer subtype relevance. |
| AKT1 | Downstream effector of PRLR signaling. | Survival and proliferation assays. |
| MAPK1 | Downstream effector of PRLR signaling. | Proliferation and differentiation. |
How Is prolactin receptor binding Regulated?
Prolactin receptor binding is regulated at multiple levels. Receptor availability is controlled by transcription factors such as ESR1, FOXA1, and GATA3. Ligand concentration is regulated by hypothalamic dopamine and prolactin-releasing factors. At the protein level, binding affinity can be modulated by glycosylation and pH; antagonists with reduced pH-dependence have been developed. Negative feedback via SOCS proteins and phosphatases terminates signaling.
prolactin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PRLR | Breast cancer | PRLR knockout breast cancer cell lines (e.g., T47D) |
| PRL | Hyperprolactinemia | PRL overexpression mouse models |
| JAK2 | Myeloproliferative neoplasms | JAK2 V617F knock-in cells |
| STAT5A | Leukemia | STAT5A knockout hematopoietic cells |
| SOCS1 | Cancer immune evasion | SOCS1 knockout mice |
Prolactin receptor binding in breast cancer
In breast cancer, autocrine prolactin loops stimulate proliferation and survival through PRLR-JAK2-STAT5 signaling. High PRLR expression correlates with poor prognosis in some subtypes. Targeting this interaction with antagonists or inhibitors is a therapeutic strategy.
Prolactin receptor binding in prostate cancer
Prostate cancer cells often express PRLR, and prolactin acts as a growth factor. Blocking prolactin receptor binding reduces tumor growth in preclinical models.
Prolactin receptor binding in endocrine disorders
Hyperprolactinemia, caused by excessive prolactin secretion, leads to galactorrhea, amenorrhea, and infertility. Dopamine agonists reduce prolactin levels, but antagonists of receptor binding are also explored.
From prolactin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PRLR loss affect tumor growth? | PRLR knockout cell line via CRISPR |
| Does a point mutation in PRLR alter binding affinity? | Point mutation knock-in (e.g., PRLR W72A) |
| Can a tagged PRLR track receptor dynamics? | Knock-in of fluorescent tag (e.g., GFP-PRLR) |
| Does PRL overexpression drive hyperplasia? | PRL overexpression transgenic model |
| What genes mediate prolactin resistance? | CRISPR library screening |
| Does a specific antagonist block binding? | Competitive binding assay with mutant PRLR |
How to Study the prolactin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity (Kd) and receptor number (Bmax) | Characterizing PRLR antagonists |
| Surface plasmon resonance | Real-time binding kinetics | Measuring kon/koff of PRL-PRLR |
| Western blot | STAT5 phosphorylation | Assessing pathway activation |
| Immunoprecipitation | Receptor-ligand complexes | Detecting dimerization |
| CRISPR knockout | Gene function | Validating PRLR as target |
| RNA-seq | Transcriptional changes | Identifying prolactin-responsive genes |
| Proximity ligation assay | In situ receptor dimerization | Visualizing binding in cells |
Binding assays
Radioligand binding assays using 125I-prolactin are the gold standard for measuring prolactin receptor binding affinity and specificity. They enable calculation of Kd and Bmax.
Structural biology
X-ray crystallography and cryo-EM have revealed the ordered binding mechanism of prolactin to its receptor, identifying key contact residues.
Mutagenesis and functional assays
Site-directed mutagenesis of PRL or PRLR followed by binding and signaling assays (e.g., STAT5 phosphorylation) maps functional epitopes.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that modulate prolactin receptor binding and downstream signaling, revealing novel therapeutic targets.
How CRISPR Can Be Used to Study GO:0005148 prolactin receptor binding
Knockout
CRISPR knockout of PRLR or PRL eliminates prolactin receptor binding and downstream signaling, providing a clean background to study receptor function and to validate drug targets.
Point Mutation
Point mutations in the ligand-binding domain of PRLR (e.g., W72A) can be introduced to dissect the contribution of specific residues to binding affinity and specificity.
Knock-in
Knock-in of epitope tags (e.g., HA, GFP) or disease-associated mutations allows tracking of receptor localization and dynamics in live cells.
Overexpression
Overexpression of PRL or PRLR via CRISPR activation or lentiviral delivery mimics autocrine loops in cancer and tests oncogenic potential.
How EDITGENE Supports prolactin receptor binding Research
Researchers studying prolactin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor activation, signaling, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for prolactin receptor binding research.
Frequently Asked Questions About prolactin receptor binding
What is prolactin receptor binding?
Prolactin receptor binding (GO:0005148) is the molecular function of a ligand, typically prolactin, binding to the prolactin receptor, initiating signaling.
What genes are involved in prolactin receptor binding?
Key genes include PRL (prolactin) and PRLR (prolactin receptor), as well as downstream effectors like JAK2 and STAT5.
How does prolactin bind to its receptor?
Prolactin binds via an ordered two-site mechanism: first to site 1, then site 2, leading to receptor dimerization and activation.
What diseases are associated with prolactin receptor binding?
Dysregulation is linked to breast cancer, prostate cancer, and hyperprolactinemia.
What is the role of PRLR in cancer?
PRLR mediates proliferative and survival signals in breast and prostate cancers, making it a therapeutic target.
How can I study prolactin receptor binding in the lab?
Common methods include radioligand binding assays, surface plasmon resonance, and CRISPR knockout models.
What are prolactin receptor antagonists?
Antagonists are molecules that block prolactin binding to its receptor, used to inhibit signaling in disease.
Can CRISPR be used to study prolactin receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of binding mechanisms.
What is the clinical significance of prolactin receptor binding?
It is critical for lactation, reproduction, and immune function, and its dysregulation contributes to cancer and endocrine disorders.
Where can I find validated antibodies for PRLR?
Commercial suppliers offer validated antibodies; however, functional validation via knockout is recommended.
Conclusion
Prolactin receptor binding (GO:0005148) is a fundamental molecular function that governs diverse physiological processes and is implicated in major diseases such as breast and prostate cancer. Understanding its ordered binding mechanism and regulation provides opportunities for therapeutic intervention. CRISPR-based models are invaluable for dissecting the causal roles of PRL, PRLR, and downstream effectors, and EDITGENE offers the tools to accelerate this research.
References
- 1. Chasseloup F et al.. 2024. Prolactin: structure, receptors, and functions.. Rev Endocr Metab Disord 25(6):953-966 PMID: 39476210
- 2. Kuo CB et al.. 1998. Prolactin receptor antagonists.. Endocrine 9(2):121-31 PMID: 9867245
- 3. Standing D et al.. 2022. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.. Front Endocrinol (Lausanne) 13:1112987 PMID: 36714582
- 4. Brooks CL et al.. 1982. Calculating specific binding for prolactin receptor assays.. Mol Cell Endocrinol 26(1-2):81-94 PMID: 6282673
- 5. Sivaprasad U et al.. 2004. Mechanism for ordered receptor binding by human prolactin.. Biochemistry 43(43):13755-65 PMID: 15504038
- 6. Hansen MJ et al.. 2011. Development of prolactin receptor antagonists with reduced pH-dependence of receptor binding.. J Mol Recognit 24(4):533-47 PMID: 20842635
- 7. Rozakis-Adcock M et al.. 1991. Mutational analysis of the ligand-binding domain of the prolactin receptor.. J Biol Chem 266(25):16472-7 PMID: 1885580
- 8. Kinet S et al.. 1996. Characterization of lactogen receptor-binding site 1 of human prolactin.. J Biol Chem 271(24):14353-60 PMID: 8662911
